A Phase 2a Study of ly4005130 in Adults with Severe Alopecia Areata

2 1

What is this study about?

The study focuses on adults with severe Alopecia Areata, an autoimmune condition that causes sudden, patchy hair loss. Participants will receive an intravenous (through a vein) infusion of the experimental drug LY4005130 or a placebo. The purpose of the study is to compare the effectiveness of LY4005130 with placebo in reducing hair loss in this population.

During the trial, participants are randomly assigned to receive either the study drug or placebo, and neither the participants nor the study staff know which treatment is given (double‑blind). The study lasts several weeks, with regular clinic visits for the infusion and monitoring of safety. Hair growth is measured using the SALT score, which rates the amount of scalp covered by hair, and a lower score indicates improvement. Simple explanations are provided at each visit to help participants understand the procedures and any medical terms used.

1 randomization and baseline assessment

after joining the study, you are assigned by a computer system to receive either ly4005130 or the placebo sub12581mig without knowing which one you receive.

a baseline visit is scheduled where your hair loss severity and overall health are recorded.

2 first infusion

on the day of the first visit, an intravenous (through a vein) infusion is given.

the infusion contains either ly4005130 at a dose of 0 mg (solution for injection) or the matching placebo, administered according to the study protocol.

3 treatment period

additional infusions are given at the intervals defined by the protocol; the exact schedule is followed by the study staff.

each infusion is performed in the same manner as the first, using the same dose and route.

4 safety and efficacy monitoring

regular visits are scheduled to check for side effects and to measure changes in hair loss using the severity of alopecia tool (salt).

these visits continue throughout the study period, which runs from may 31 2026 to july 27 2026.

5 final evaluation

at the end of the study, a final assessment is performed to determine whether the percentage of participants with a salt score of 20 or less has changed.

the results are recorded and the trial is concluded.

Who Can Join the Study?

You have severe Alopecia Areata (AA), a strong form of the condition that causes hair loss.
Your hair loss covers at least 50% but no more than 90% of your scalp, measured with the Severity of Alopecia Tool (SALT) score, a scale doctors use to count the area without hair.
The current episode of severe AA has lasted at least 6 months and no longer than 4 years.
In the doctor’s opinion, you have not had any noticeable spontaneous hair regrowth (hair growing back on its own) for at least 6 months.
You agree not to use any other AA treatments (medicines or therapies for Alopecia Areata) while in the study.
Both men and women are eligible to join the study.
You must be within the age range set by the study.

Who Cannot Join the Study?

Having the diffuse type of alopecia areata, which means hair loss is spread out over the scalp rather than in patches.
Currently having any other type of alopecia (different forms of hair loss).
Having a serious or unstable additional illness that often needs hospital stays or the regular use of strong medicines that lower the immune system (systemic immunosuppressants).
Having taken oral JAK inhibitors (pills that affect the immune system) before joining the study.
Having had a major operation within the last 8 weeks before screening, or needing a major operation during the study.
Having a history or current problem with any serious condition such as:
- Cardiovascular disorders (heart or blood‑vessel problems),
- Respiratory disorders (lung or breathing problems),
- Hepatic disorders (liver problems),
- Gastrointestinal disorders (stomach or intestine problems),
- Endocrine disorders (hormone problems),
- Hematological disorders (blood problems),
- Neurological disorders (nerve or brain problems),
- Neuropsychiatric disorders (mental health or behavior problems), or any other serious and/or unstable illness.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Diamond Clinic Sp. z o.o.	Cracow	Poland

Other Sites

Site Name	City	Country
Gsovrrilep Rryudqll Sny z othe	Wroclaw	Poland
Esgzluz Ugptvtvybmvq Mcrxvem Cmygvje Ruzeoxivo (odxfcwe Mrm	Rotterdam	The Netherlands
Cpdvdru Bhqny Kjuwqxkehka Pygywqcg Sdx z ovcr	Gdansk	Poland
Zmjotea Mze Sum z otdr	Lublin	Poland

Trial status

Country	Status	Recruitment Start
Poland	Not yet recruiting	31.05.2026
The Netherlands	Not yet recruiting	31.05.2026

Trial locations

LY4005130 is an experimental medicine being tested to see if it can help people with severe alopecia areata, a condition that causes large patches of hair loss. In this study the drug is given as a sterile liquid that is injected into a vein (intravenous use). Researchers are looking at whether the medicine can promote hair regrowth and be safe for patients.

Alopecia Areata – Alopecia Areata is an autoimmune condition that causes sudden hair loss in patches on the scalp or other body areas. The immune system mistakenly attacks hair follicles, leading to hair shedding. The patches can appear quickly and may expand over weeks or months. In some people the condition remains limited to small areas, while in others it can spread to larger portions of the scalp. The pattern of hair loss can change over time, with new spots developing and some areas regrowing hair intermittently.

Trial ID:

2025-524727-41-00

Protocol code:

J5D-MC-FPAC

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

A Phase 2a Study of ly4005130 in Adults with Severe Alopecia Areata

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?